Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, MI.
Department of Anesthesiology, Chronic Pain and Fatigue Research Center University of Michigan Medical School, Ann Arbor, MI; and.
Cornea. 2024 Nov 1;43(11):1335-1339. doi: 10.1097/ICO.0000000000003646. Epub 2024 Jul 23.
Chronic ocular pain (COP) is a leading cause of eye care visits in the US and has a substantial impact on quality of life and visual functioning. Although many conditions underlie COP, such as dry eye disease or post-herpetic neuralgia, some people experience pain without significant ocular signs on examination or known risk factors (eg, traumatic injury). Antidepressant medications that act primarily on the central nervous system, such as tricyclic antidepressants and serotonin and norepinephrine reuptake inhibitors, are often used to treat patients with COP, but a recent Cochrane review and network meta-analysis investigating 25 different antidepressants concluded that only two serotonin and norepinephrine reuptake inhibitors, have sufficient data to support their use in chronic pain. For all other medications, the evidence was of low certainty. We contend that while these medications are not a cure-all for chronic pain or COP, it is premature to conclude that these medications have no role in their treatment. We provide a rationale for continued use of antidepressant medications as part of a multimodal targeted treatment for patients with COP.
慢性眼部疼痛(COP)是美国眼科就诊的主要原因,对生活质量和视觉功能有重大影响。虽然许多疾病都可引起 COP,如干眼症或带状疱疹后神经痛,但有些人在检查时没有明显的眼部体征或已知的危险因素(如创伤性损伤)也会感到疼痛。主要作用于中枢神经系统的抗抑郁药物,如三环类抗抑郁药和 5-羟色胺和去甲肾上腺素再摄取抑制剂,常用于治疗 COP 患者,但最近一项 Cochrane 综述和网络荟萃分析调查了 25 种不同的抗抑郁药,得出的结论是,只有两种 5-羟色胺和去甲肾上腺素再摄取抑制剂有足够的数据支持其用于慢性疼痛。对于所有其他药物,证据的确定性都较低。我们认为,虽然这些药物并不是治疗慢性疼痛或 COP 的万能药,但过早地得出这些药物在治疗中没有作用的结论还为时过早。我们为继续使用抗抑郁药物作为 COP 患者多模式靶向治疗的一部分提供了一个理由。